课题基金 / 基金详情

Druggable Mechanisms

Druggable Mechanisms
药物机制
批准号:
8532051
负责人:
YOSHIHIRO NAKATANI
金额:
$33.66万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2004
资助国家:
美国
项目状态:
未结题
起止时间:
2004-07-01 至

项目摘要

项目成果

YOSHIHIRO NAKATANI的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The overriding objective of the Druggable Mechanisms Core (DMC) is to provide state-of-the-art technologies in high-throughput chromatin-immunoprecipitation sequencing (ChlP-seq), RNA sequencing (RNA-seq), and mass spectrometry-based proteomics to each Project for in-depth characterization of transcription factor protein complexes and their respective genetic targets. Data from the DMC will reveal interacting protein partners for Olig1 (Project 1), Runx1 (Project 2), and NPAS4 (Project 3), characterize associated post-translational modifications, identify downstream genetic targets, and finally quantify the coordinate action of these protein-protein and protein-DNA interactions with respect to transcription of respective target genes. The comprehensive view of molecular interactions provided by the DMC will encompass both direct and surrogate therapeutic entry points for neuropathologies associated with Olig1, Runx1, and NPAS4. Over time the synergy established between the DMC and Projects 1-3 may provide an experimental paradigm for transcription factor-directed drug discovery. The specific aims of the DMC are: 1.) Implement innovative mass spectrometry-based proteomics techniques for analysis of protein complexes. We will implement novel proteomics methods to improve dynamic range of protein and peptide identification in conjunction with tandem immunoaffinity purification of protein complexes. These will include solid-phase capture of cysteine-containing peptides combined with stable isotope labeling for quantitative proteomics, and a multidimension separation strategy based on a combination of reversed phase resins (RP/RP). 2.) Develop ChlP-seq and RNA-seq libraries and optimize sequencing on an Applied Biosystems SOLID genome analyzer. The goal of this aim will be to develop reliable ChlP-seq and RNA-seq library construction protocols. Each project will require short read sequencing, which we will perform on our SOLiD genome analyzer. Continuous development of in-house protocols in consultation with AppliedBiosystems will ensure efficient and rapid sequencing on our SOLiD instrument. 3.) Deploy web-based, bioinformatic tools for integrated analysis of ChIP- an RNA-seq data and for comprehensive, user-driven analysis of proteomics data. The goal of this aim is to deploy a web-based system that will provide personnel in Projects 1-3 with an interactive, comprehensive, and dynamic computational platform for interrogation of their genomic and proteomic data, and extension of their observations to the level of pathways and networks.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
How do Tumor Cells Gain Anchorage Independency?
  • 批准号:
    8204485
  • 项目类别:
  • 资助金额:
    $35.22万
  • 财政年份:
    2010
  • 负责人:
    YOSHIHIRO NAKATANI
  • 依托单位:
How do Tumor Cells Gain Anchorage Independency?
  • 批准号:
    7887339
  • 项目类别:
  • 资助金额:
    $36.04万
  • 财政年份:
    2010
  • 负责人:
    YOSHIHIRO NAKATANI
  • 依托单位:
How do Tumor Cells Gain Anchorage Independency?
  • 批准号:
    8408805
  • 项目类别:
  • 资助金额:
    $33.11万
  • 财政年份:
    2010
  • 负责人:
    YOSHIHIRO NAKATANI
  • 依托单位:
How do Tumor Cells Gain Anchorage Independency?
  • 批准号:
    8022878
  • 项目类别:
  • 资助金额:
    $35.22万
  • 财政年份:
    2010
  • 负责人:
    YOSHIHIRO NAKATANI
  • 依托单位:
国内基金
海外基金
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
  • 批准号:
    32170319
  • 项目类别:
    面上项目
  • 资助金额:
    58.00万元
  • 批准年份:
    2021
  • 负责人:
    董春海
  • 依托单位:
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
  • 批准号:
    --
  • 项目类别:
    --
  • 资助金额:
    58万元
  • 批准年份:
    2021
  • 负责人:
    董春海
  • 依托单位:
ID1 (Inhibitor of DNA binding 1) 在口蹄疫病毒感染中作用机制的研究
番茄EIN3-binding F-box蛋白2超表达诱导单性结实和果实成熟异常的机制研究
  • 批准号:
    31372080
  • 项目类别:
    面上项目
  • 资助金额:
    80.0万元
  • 批准年份:
    2013
  • 负责人:
    杨迎伍
  • 依托单位: